名臣健康(002919) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 126,485,288.71, an increase of 10.09% year-on-year [7]. - Net profit attributable to shareholders was CNY 7,738,253.15, representing a growth of 28.44% compared to the same period last year [7]. - Basic earnings per share were CNY 0.06, up by 20.00% year-on-year [7]. - The weighted average return on net assets was 1.38%, an increase of 0.27% compared to the previous year [7]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,943,223.86, a substantial increase of 65.38% [7]. - The company reported a net profit of CNY 20,754,212.41 for the year-to-date, a decrease of 18.58% compared to the same period last year [7]. - Total operating revenue for Q3 2019 was CNY 126,485,288.71, an increase of 10.4% compared to CNY 114,890,419.33 in the same period last year [35]. - Net profit for Q3 2019 reached CNY 7,738,253.15, representing a 28.5% increase from CNY 6,024,605.81 in Q3 2018 [36]. - The total comprehensive income for Q3 2019 was CNY 7,738,253.15, an increase from CNY 6,024,605.81 in Q3 2018 [39]. - The total profit for Q3 2019 was CNY 13,299,653.34, a decrease from CNY 15,721,580.16 in Q3 2018 [39]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 695,329,104.10, a decrease of 0.48% compared to the end of the previous year [7]. - Total assets decreased slightly to ¥695,329,104.10 from ¥698,664,409.44 [26]. - Total liabilities decreased to ¥131,821,339.36 from ¥147,668,474.11 [27]. - The company's total assets as of September 30, 2019, were CNY 661,350,458.19, slightly down from CNY 663,596,240.52 at the end of 2018 [33]. - Current assets totaled CNY 564,925,414.57, a decrease from CNY 572,227,250.73 at the end of 2018 [31]. - The total equity attributable to shareholders of the parent company was CNY 583,740,495.22, up from CNY 556,885,509.66 [33]. - The company's total equity amounted to 550,895,935.33 CNY, remaining stable compared to the previous period [62]. Cash Flow - Net cash flow from operating activities reached CNY 41,584,255.00, a significant increase of 142.80% [7]. - Cash flow from operating activities improved by 64.34% to -¥15,359,361.22, attributed to increased cash received from sales [15]. - Investment activities generated a net cash flow of ¥45,294,987.95, a 122.25% increase due to the recovery of investments [15]. - Cash flow from operating activities showed a net outflow of CNY 15,359,361.22, an improvement from a net outflow of CNY 43,067,577.85 in the previous period [51]. - The company reported a decrease in cash outflow from financing activities to 8,186,279.05 CNY from 17,988,500.32 CNY in the previous period [57]. - The net increase in cash and cash equivalents for the period was 15,353,168.63 CNY, a recovery from a decrease of 260,609,693.96 CNY in the prior period [57]. Shareholder Information - The total number of shareholders at the end of the reporting period was 12,914 [11]. - The largest shareholder, Chen Qinfang, holds 49.34% of the shares, amounting to 60,258,000 shares, with 23,250,000 shares pledged [11]. Expenses - Total operating costs for Q3 2019 were CNY 118,294,865.55, up from CNY 110,976,223.99, reflecting a growth of 6.0% [35]. - The total operating costs for the year-to-date period were CNY 339,096,775.24, down from CNY 351,810,293.42 in the previous year [42]. - Research and development expenses for Q3 2019 were CNY 3,730,484.23, slightly up from CNY 3,719,687.04 in the previous year [35]. - Research and development expenses increased to CNY 11,081,599.37, up from CNY 10,046,960.37, indicating a growth of 10.3% [48]. - The company reported a decrease in sales expenses to CNY 11,343,129.23 from CNY 15,142,999.47, a reduction of approximately 25.5% [47]. Other Financial Metrics - The company reported a significant decrease of 84.79% in other income to ¥220,625.00 due to reduced government subsidies [15]. - The company’s capital stock increased by 50.00% to ¥122,135,745.00 due to the conversion of capital reserves into share capital [15]. - The company has no overdue commitments from controlling shareholders or related parties during the reporting period [16]. - The company received 390,000,000.00 CNY from investment recoveries, significantly higher than 210,000,000.00 CNY in the last period [56]. - The company reported an investment income of CNY 2,103,726.04 for Q3 2019, compared to CNY 2,377,621.31 in the same period last year [39].